MAAT Maat Pharma SA

Regulatory News:

MaaT Pharma (EURONEXT: MAAT – the “Company”), a clinical-stage biotechnology company and a leader in the development of Microbiome Ecosystem TherapiesTM (MET) dedicated to enhancing survival for patients with cancer, today announces its half-year report on the liquidity contract with the brokerage firm Kepler Cheuvreux.

Under the liquidity agreement entrusted by MaaT Pharma to Kepler Cheuvreux, the following resources were listed on the liquidity account on December 31st, 2023:

• 24,236 shares
• € 34,107.60
• Number of executions on buy side on semester: 627
• Number of executions on sell side on semester: 368
• Traded volume on buy side on semester: 18,328 shares for € 122,340.49
• Traded volume on sell side on semester: 9,576 shares for € 64,693.03

As a reminder:

• the following resources appeared on the last half year statement on June 30, 2023 on the liquidity account:
  • 15,484 shares
  • € 41,285.13
• Number of executions on buy side on semester: 552
• Number of executions on sell side on semester: 431
• Traded volume on buy side on semester: 15,974 shares for € 144,745.75
• Traded volume on sell side on semester: 12,997 shares for € 122,384.16

The following resources appeared on the liquidity account when the activity started:

• 0 shares
• € 200,000.00

The liquidity contract has been in effect since March 14, 2022, in accordance with the authorization granted by the General Meeting on March 3, 2022, and renewed on June 19, 2023. The implementation of this report is carried out in accordance with AMF Decision N°2021-01 of June 22, 2021, renewing the implementation of liquidity contracts for shares as an accepted market practice.

  Buy side   Sell side   Number of executions Number of shares Traded volume in EUR   Number of executions Number of shares Traded volume in EUR Total

627

18,328

122,340.49

 

368

9,576

64,693.03

03/07/2023

5

447

3,111.12

 

-

-

-

04/07/2023

21

845

5,391.10

 

-

-

-

05/07/2023

4

284

1,848.84

 

1

1

6.90

06/07/2023

4

111

747.03

 

1

1

6.84

07/07/2023

3

70

466.20

 

-

-

-

10/07/2023

-

-

-

 

1

50

335.00

12/07/2023

1

30

201.00

 

-

-

-

13/07/2023

3

20

133.00

 

-

-

-

14/07/2023

1

1

6.62

 

1

1

6.62

17/07/2023

3

110

715.00

 

-

-

-

18/07/2023

3

100

640.00

 

-

-

-

19/07/2023

1

20

128.00

 

2

40

258.40

20/07/2023

1

40

256.00

 

1

50

323.00

21/07/2023

1

40

256.00

 

-

-

-

24/07/2023

-

-

-

 

1

30

192.60

25/07/2023

2

21

134.40

 

1

1

6.40

26/07/2023

2

51

325.38

 

1

1

6.38

27/07/2023

1

50

320.00

 

4

66

423.72

28/07/2023

3

100

633.00

 

2

54

345.60

31/07/2023

3

100

621.00

 

3

71

454.40

01/08/2023

1

50

320.00

 

4

129

833.34

02/08/2023

2

80

508.00

 

-

-

-

03/08/2023

-

-

-

 

3

50

320.00

04/08/2023

5

31

195.30

 

1

1

6.30

07/08/2023

-

-

-

 

1

20

128.00

08/08/2023

1

20

128.00

 

-

-

-

09/08/2023

2

24

152.16

 

-

-

-

10/08/2023

1

1

6.38

 

1

1

6.38

11/08/2023

1

1

6.38

 

2

7

44.80

14/08/2023

4

50

315.00

 

-

-

-

15/08/2023

1

1

6.32

 

2

31

198.40

16/08/2023

3

31

195.30

 

1

1

6.38

17/08/2023

1

10

63.00

 

1

20

128.00

18/08/2023

2

21

132.30

 

1

1

6.38

21/08/2023

-

-

-

 

2

50

320.00

22/08/2023

2

41

258.30

 

1

1

6.38

23/08/2023

3

30

188.70

 

2

60

382.20

24/08/2023

3

30

189.00

 

1

20

128.00

25/08/2023

6

116

709.92

 

5

94

579.98

28/08/2023

5

90

547.20

 

2

11

69.30

29/08/2023

4

31

192.20

 

3

48

304.32

30/08/2023

6

370

2,353.20

 

-

-

-

31/08/2023

5

109

683.43

 

-

-

-

05/09/2023

1

1

6.30

 

1

1

6.30

06/09/2023

1

1

6.32

 

1

1

6.32

07/09/2023

7

248

1,550.00

 

3

150

969.00

08/09/2023

5

244

1,520.12

 

2

151

966.40

11/09/2023

2

6

38.04

 

-

-

-

12/09/2023

7

344

2,132.80

 

4

100

626.00

13/09/2023

2

31

195.30

 

5

81

515.16

14/09/2023

1

20

126.00

 

1

20

128.00

18/09/2023

4

151

943.75

 

3

80

500.80

19/09/2023

5

60

369.00

 

2

21

130.20

20/09/2023

2

10

63.00

 

4

80

511.20

21/09/2023

4

100

618.00

 

1

50

315.00

22/09/2023

7

239

1,465.07

 

1

1

6.28

25/09/2023

4

110

684.20

 

2

50

313.00

26/09/2023

9

430

2,558.50

 

2

50

314.50

27/09/2023

12

791

4,445.42

 

5

122

744.20

28/09/2023

12

710

3,564.20

 

2

200

1,008.00

29/09/2023

2

50

252.00

 

5

300

1,554.00

02/10/2023

3

130

661.70

 

-

-

-

03/10/2023

18

540

2,624.40

 

11

400

2,000.00

04/10/2023

3

130

666.90

 

3

110

569.80

05/10/2023

3

234

1,404.00

 

18

588

3,580.92

06/10/2023

2

50

313.00

 

3

60

379.80

09/10/2023

9

190

1,155.20

 

-

-

-

10/10/2023

5

105

628.95

 

2

30

183.00

11/10/2023

9

167

993.65

 

3

49

300.37

12/10/2023

1

1

5.82

 

4

51

306.00

13/10/2023

6

73

427.78

 

2

23

140.30

16/10/2023

1

99

588.06

 

1

48

288.00

17/10/2023

2

11

66.00

 

1

1

5.98

18/10/2023

3

35

211.75

 

3

39

239.85

19/10/2023

6

139

849.29

 

3

80

498.40

20/10/2023

3

8

48.72

 

2

21

129.99

23/10/2023

4

67

414.73

 

1

20

124.00

24/10/2023

5

74

454.36

 

2

21

130.20

25/10/2023

2

18

111.60

 

1

1

6.22

26/10/2023

-

-

-

 

8

339

2,278.08

27/10/2023

5

140

974.40

 

4

49

348.88

30/10/2023

6

90

632.70

 

1

21

151.20

31/10/2023

2

40

286.40

 

12

354

2,708.10

01/11/2023

4

400

3,164.00

 

10

338

2,879.76

02/11/2023

19

1,720

13,553.60

 

-

-

-

03/11/2023

22

1,108

8,110.56

 

-

-

-

06/11/2023

5

77

599.83

 

5

82

655.18

07/11/2023

5

95

787.55

 

8

140

1,164.80

08/11/2023

7

125

1,028.75

 

1

20

166.00

09/11/2023

10

207

1,674.63

 

2

6

49.80

10/11/2023

20

216

1,736.64

 

1

1

8.06

13/11/2023

11

117

932.49

 

-

-

-

14/11/2023

4

69

539.58

 

4

48

379.68

15/11/2023

11

270

2,060.10

 

4

140

1,104.60

16/11/2023

5

121

917.18

 

4

75

574.50

17/11/2023

3

90

695.70

 

-

-

-

20/11/2023

10

484

3,562.24

 

4

61

461.16

21/11/2023

13

303

2,172.51

 

3

92

678.96

22/11/2023

4

63

451.71

 

3

43

313.90

23/11/2023

4

93

675.18

 

-

-

-

24/11/2023

4

65

467.35

 

-

-

-

27/11/2023

8

161

1,122.17

 

1

1

7.14

28/11/2023

6

140

952.00

 

3

110

767.80

29/11/2023

3

200

1,380.00

 

1

1

6.96

30/11/2023

5

140

945.00

 

2

90

610.20

01/12/2023

21

389

2,594.63

 

13

415

3,037.80

04/12/2023

2

100

685.00

 

5

147

1,043.70

05/12/2023

-

-

-

 

2

65

455.00

06/12/2023

1

17

118.32

 

3

75

525.00

07/12/2023

11

349

2,348.77

 

3

90

618.30

08/12/2023

15

251

1,641.54

 

4

61

405.65

11/12/2023

7

154

1,057.98

 

22

1,083

7,873.41

12/12/2023

4

48

340.80

 

9

300

2,145.00

13/12/2023

13

238

1,635.06

 

-

-

-

14/12/2023

4

60

403.20

 

3

60

409.80

15/12/2023

9

190

1,271.10

 

11

300

2,055.00

18/12/2023

4

20

135.60

 

2

15

102.30

19/12/2023

5

71

484.22

 

5

21

143.43

20/12/2023

5

60

418.20

 

10

225

1,579.50

21/12/2023

10

92

623.76

 

4

81

568.62

22/12/2023

10

137

946.67

 

15

261

1,827.00

27/12/2023

4

75

536.25

 

8

210

1,507.80

28/12/2023

3

35

250.25

 

4

80

583.20

29/12/2023

11

314

2,179.16

 

8

165

1,166.55

About MaaT Pharma MaaT Pharma, a clinical stage biotechnology company, has established a complete approach to restoring patient-microbiome symbiosis in oncology. Committed to treating cancer and graft-versus-host disease (GvHD), a serious complication of allogeneic stem cell transplantation, MaaT Pharma has launched, in March 2022, an open-label, single arm Phase 3 clinical trial in patients with acute GvHD, following the achievement of its proof of concept in a Phase 2 trial. Its powerful discovery and analysis platform, gutPrint®, enables the identification of novel disease targets, evaluation of drug candidates, and identification of biomarkers for microbiome-related conditions. The company’s Microbiome Ecosystem Therapies are produced through a standardized cGMP manufacturing and quality control process to safely deliver the full diversity of the microbiome, in liquid and oral formulations. MaaT Pharma benefits from the commitment of world-leading scientists and established relationships with regulators to support the integration of the use of microbiome therapies in clinical practice. MaaT Pharma is listed on Euronext Paris (ticker: MAAT).

View source version on businesswire.com: https://www.businesswire.com/news/home/20240122876130/en/

MaaT Pharma – Investor Relations Guilhaume DEBROAS, Ph.D. Head of Investor Relations +33 6 16 48 92 50 invest@maat-pharma.com

MaaT Pharma – Media Relations Pauline RICHAUD Senior PR & Corporate Communications Manager +33 6 14 06 45 92 media@maat-pharma.com

Trophic Communications – Corporate Communications Stephanie MAY or Priscilla PERRIN +49 171 351 2733 maat@trophic.eu